Dublin Core
Title
Metabolism and Metabolomics of Liver in Health and Disease
Subject
Metabolism
Heart diseases in women
Description
Women and men have probably never been concerned as much by their health as during this COVID-19 pandemic. In this context, lifestyle habits continue to be promoted as allies for daily prevention against diseases. This is valid also for metabolic diseases, among which many affect the liver and are risk factors for aggravating the disease course of COVID-19. In fact, liver diseases are currently a major global health problem. There is a huge range of liver diseases and non-alcoholic fatty liver disease (NAFLD) is the most common chronic hepatic condition, which in some patients progresses to cirrhosis and liver cancer. Currently, substantial efforts are being made to better understand NAFLD, especially, because there is no U.S. Food and Drug Administration (FDA)-approved pharmacological therapy. To explore this disease, metabolomics is the most recently developed omics technology after genomics, transcriptomics, and proteomics. Metabolomics is the large-scale analysis of molecules, known as metabolites that are intermediate or end products of metabolism found within cells, tissues, and biofluids. This technology has a very high potential to identify biomarker candidates for the future development of new therapeutics. The book features articles that address metabolomics technology and its use to document different liver functions and dysfunctions, with a major focus on NAFLD.
Creator
Wahli, Walter (editor)
Guillou, Hervé (editor)
Source
https://directory.doabooks.org/handle/20.500.12854/68388
Publisher
MDPI - Multidisciplinary Digital Publishing Institute
Publisher website
www.mdpi.com/books
Date
2021
Contributor
Sukartini
Rights
https://creativecommons.org/licenses/by/4.0/
Relation
Estes, C.; Razavi, H.; Loomba, R.; Younossi, Z.; Sanyal, A.J. Modeling the epidemic of nonalcoholic fatty liver
disease demonstrates an exponential increase in burden of disease. Hepatology 2018, 67, 123–133. [CrossRef]
[PubMed]
disease demonstrates an exponential increase in burden of disease. Hepatology 2018, 67, 123–133. [CrossRef]
[PubMed]
Sanyal, A.J. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol.
Hepatol. 2019, 16, 377–386. [CrossRef]
Hepatol. 2019, 16, 377–386. [CrossRef]
Format
Pdf
Language
English
Type
Textbooks
Identifier
DOI
10.3390/books978-3-03943-636-1
10.3390/books978-3-03943-636-1
ISBN
9783039436354, 9783039436361
9783039436354, 9783039436361
Coverage
Basel, Switzerland